NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.07 by $0.95. The biopharmaceutical company had revenue of $25.72 million for the quarter. AVEO Pharmaceuticals had a negative return on equity of 561.43% and a net margin of 120.85%. View AVEO Pharmaceuticals' Earnings History.

AVEO Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for AVEO Pharmaceuticals.

3 Wall Street analysts have issued 1-year price objectives for AVEO Pharmaceuticals' shares. Their forecasts range from $17.50 to $20.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 299.8% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AVEO Pharmaceuticals.

Press coverage about AVEO stock has trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a daily sentiment score of -4.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for AVEO Pharmaceuticals.

AVEO Pharmaceuticals saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 16,400,000 shares, a decline of 5.0% from the January 15th total of 17,270,000 shares. Based on an average daily volume of 1,900,000 shares, the days-to-cover ratio is presently 8.6 days. Approximately 12.2% of the company's shares are short sold. View AVEO Pharmaceuticals' Current Options Chain.

Some companies that are related to AVEO Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Amarin (AMRN), Alibaba Group (BABA), Canopy Growth (CGC), Bellicum Pharmaceuticals (BLCM) and Opko Health (OPK).

AVEO Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jacobs Levy Equity Management Inc. (0.90%), Geode Capital Management LLC (0.61%), Marshall Wace LLP (0.18%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

AVEO stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals.

AVEO stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Marshall Wace LLP and Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVEO stock can currently be purchased for approximately $4.69.

AVEO Pharmaceuticals has a market capitalization of $75.42 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.View Additional Information About AVEO Pharmaceuticals.

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]